We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+51.43%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$282M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow %
86.79%
Top 10 Hldgs %
99.48%
Holding
12
New
12
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$59.1M
2
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$52.1M
3
EPZM
Epizyme, Inc
EPZM
+$34.6M
4
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$33.3M
5
ARQL
Arqule Inc
ARQL
+$12.7M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 94.51%
2 Miscellaneous 5.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
1
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$57.7M 20.43%
+389,842
New +$59.1M
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$57.4M 20.33%
+2,331,534
New +$34.6M
TCRR
3
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$48.1M 17.06%
+3,370,982
New +$52.1M
GTHX
4
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$37.6M 13.34%
+1,423,794
New +$33.3M
ARQL
5
DELISTED
Arqule Inc
ARQL
$21.8M 7.74%
+1,094,210
New +$12.7M
DCPH
6
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$13.4M 4.75%
+215,570
New +$10.2M
ARGX icon
7
argenx
ARGX
$64B
$11.5M 4.08%
+71,700
New +$9.7M
YMAB
8
DELISTED
Y-mAbs Therapeutics
YMAB
$10.5M 3.74%
+337,291
New +$9.98M
CTMX icon
9
CytomX Therapeutics
CTMX
$699M
$7.11M 2.52%
+855,437
New +$5.77M
VIRX
10
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$949K 0.34%
+80,283
New +$1.34M
AUTL
11
Autolus Therapeutics
AUTL
$623M
$525K 0.19%
+39,740
New +$520K

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for MPM BioImpact, which disclosed 12 positions worth $282M. Its ten largest holdings account for 99% of the portfolio.

Its largest position is Harpoon Therapeutics, Inc. Common Stock: 389,842 shares worth $57.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Miscellaneous.

  • MPM BioImpact's largest Q4 2019 buy was Harpoon Therapeutics, Inc. Common Stock: 389,842 shares worth $57.7M.
  • MPM BioImpact's ten largest holdings make up 99% of its $282M portfolio in Q4 2019.
  • MPM BioImpact disclosed 12 positions in Q4 2019, its first 13F filing on record.

Based on MPM BioImpact's 13F filing for Q4 2019, filed 14 Feb 2020.